Group 1 - The company Yinos (SH 688710) announced plans to reduce its shareholding by up to approximately 1.41 million shares, which represents no more than 1% of the total share capital, within three months starting from 15 trading days after the announcement [1] - The share reduction will be conducted through centralized bidding, with the selling price determined by market conditions. Adjustments will be made to the reduction plan in case of any corporate actions such as dividends or stock splits during the implementation period [1] - As of the report, Yinos has a market capitalization of 6.3 billion yuan [1] Group 2 - For the fiscal year 2024, Yinos's revenue composition is as follows: non-clinical CRO accounts for 95.42%, clinical CRO accounts for 4.11%, other business segments account for 0.38%, and other operations account for 0.09% [1]
益诺思：股东张江生药基地计划减持公司股份不超过约141万股